Liver Disease Related to Obesity and Diabetes Rising in U.S. Liver Disease Related to Obesity and Diabetes Rising in U.S.

Reuters Health Information
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Gastroenterology News Source Type: news

Related Links:

Publication date: Available online 25 July 2019Source: Journal of Clinical and Experimental HepatologyAuthor(s): Raseen Tariq, Page Axley, Ashwani K. SingalNonalcoholic fatty liver disease (NAFLD) is now the leading cause of chronic liver disease worldwide with a strong association with metabolic syndrome. NAFLD is truly a systemic disease and is associated with a plethora of extra-hepatic manifestations or comorbidities. These are either related to secondary effects of associated obesity or from pathophysiological effects of insulin resistance in NAFLD. Three most common causes of increased morbidity and mortality associa...
Source: Journal of Clinical and Experimental Hepatology - Category: Gastroenterology Source Type: research
The objective of the present study was to investigate the association between hair and urine Al levels and obesity.MethodsA total of 206 lean and 205 obese non-occupationally exposed subjects (30-50 y.o.) were enrolled in the study. Hair and urine Al levels were assessed with ICP-MS. Laboratory quality control was performed using the certified reference materials of human hair, plasma, and urine.ResultsHair and urinary Al levels in obese subjects were significantly higher by 31% and 46% compared to the control levels, respectively. The presence of hypertension (41% cases), atherosclerosis (8%), type 2 diabetes melli...
Source: Journal of Trace Elements in Medicine and Biology - Category: Biochemistry Source Type: research
Abstract Non-Alcoholic Fatty Liver Disease (NAFLD), the most common liver disease, is characterized by accumulation of fat (>5% of the liver tissue), in the absence of alcohol abuse or other chronic liver diseases. Its prevalence is increasing because of obesity, metabolic syndrome or Type 2 Diabetes Mellitus (T2DM). NAFLD can cause liver inflammation and progress to Non-Alcoholic Steatohepatitis (NASH), fibrosis, cirrhosis or Hepatocellular Cancer (HCC). Nevertheless, Cardiovascular Disease (CVD) is the most common cause of morbidity and mortality in NAFLD/NASH patients. Current guidelines suggest the use of p...
Source: Current Vascular Pharmacology - Category: Drugs & Pharmacology Authors: Tags: Curr Vasc Pharmacol Source Type: research
This article provides a systematic mini-review of the literature concerning traditional Chinese medicine for modulation of the intestinal microbiota to ameliorate obesity, type 2 diabetes mellitus, and nonalcoholic fatty liver disease in China. Initially, the relationship between traditional Chinese medicine and intestinal microbiota was introduced, followed by specific research results on this relationship based on 25 original articles. Therefore, this mini-review will provide a complementary and integrative approach for the treatment of these obesity-related diseases.
Source: Holistic Nursing Practice - Category: Nursing Tags: FEATURES Source Type: research
Publication date: Available online 14 August 2019Source: The Lancet Diabetes &EndocrinologyAuthor(s): Fereidoun Azizi, Farzad Hadaegh, Farhad Hosseinpanah, Parvin Mirmiran, Atieh Amouzegar, Hengameh Abdi, Golaleh Asghari, Donna Parizadeh, Seyed Ali Montazeri, Mojtaba Lotfaliany, Farzin Takyar, Davood KhaliliSummaryThe Middle East and north Africa are home to different populations with widely varying cultures, histories, and socioeconomic settings. Hence, their health status, health management, and access to appropriate health care differ accordingly. In this Review, we examine data on the historical and prospective sta...
Source: The Lancet Diabetes and Endocrinology - Category: Endocrinology Source Type: research
(Reuters Health) - The only liver disease becoming more widespread in the U.S. is one driven by obesity and diabetes, even as other types of liver disorders linked to drinking or hepatitis are becoming less common, researchers say.
Source: Reuters: Health - Category: Consumer Health News Tags: healthNews Source Type: news
Publication date: Available online 13 August 2019Source: Clinica Chimica ActaAuthor(s): Xin Su, Yi Kong, Daoquan PengAbstractNon-alcoholic fatty liver disease (NAFLD) is one of the most common liver diseases in several developed countries, ranging from simple non-alcoholic fatty liver (NAFL) to non-alcoholic steatohepatitis (NASH) and cirrhosis. Currently, NAFLD has been confirmed to be associated with dyslipidemia, insulin resistance, and pre-diabetes, which are always grouped together as metabolic syndrome. Fibroblast growth factor 21 (FGF21) plays an important role in liver pathophysiology with multiple metabolic functi...
Source: Clinica Chimica Acta - Category: Laboratory Medicine Source Type: research
Conclusion.Results of this study suggest that inhibition of estrogen synthesis in postmenopausal women undergoing treatment with aromatase inhibitors could increase the risk of NAFLD, which might have some influence on the prognosis of patients with breast cancer.Implications for Practice.Unlike tamoxifen, the role of aromatase inhibitor treatment use in postmenopausal patients with breast cancer in development of fatty liver is not well known. In this propensity‐matched cohort study, postmenopausal patients with breast cancer treated with aromatase inhibitors had increased risk of nonalcoholic fatty liver disease compar...
Source: The Oncologist - Category: Cancer & Oncology Authors: Tags: Breast Cancer Source Type: research
CONCLUSION: We conclude that in non-diabetic, severely obese humans, excess intrahepatic lipid is associated with limited export of triglyceride in VLDL particles rather than increased uptake of systemic free fatty acids. PMID: 31408176 [PubMed - as supplied by publisher]
Source: The Journal of Clinical Endocrinology and Metabolism - Category: Endocrinology Authors: Tags: J Clin Endocrinol Metab Source Type: research
Abstract Non-alcoholic fatty liver disease (NAFLD) is one of the most common liver diseases in several developed countries, ranging from simple non-alcoholic fatty liver (NAFL) to non-alcoholic steatohepatitis (NASH) and cirrhosis. Currently, NAFLD has been confirmed to be associated with dyslipidemia, insulin resistance, and pre-diabetes, which are always grouped together as metabolic syndrome. Fibroblast growth factor 21 (FGF21) plays an important role in liver pathophysiology with multiple metabolic functions. Accumulating evidence has shown that FGF21 could directly modulate lipid metabolism and reduce lipid a...
Source: International Journal of Clinical Chemistry - Category: Chemistry Authors: Tags: Clin Chim Acta Source Type: research
More News: Diabetes | Eating Disorders & Weight Management | Endocrinology | Gastroenterology | Health | Liver | Liver Disease | Obesity | Urology & Nephrology